Standard BioTools Reports Q4 & FY25 Results, Holds $550M Cash Post-SomaLogic Sale, Guides Lower for 2026

summarizeSummary

Standard BioTools reported declining Q4 and FY25 revenue from continuing operations and issued lower 2026 guidance, but highlighted a strong balance sheet with approximately $550 million in cash and investments following the SomaLogic divestiture, intended to fuel inorganic growth.

check_boxKey Events

• Reports Q4 and Full Year 2025 Financial Results

  Revenue from continuing operations was $23.8 million for Q4 2025 (down 4% YoY) and $85.3 million for FY 2025 (down 6% YoY). Net income for Q4 2025 was $13.9 million, primarily due to a non-cash $38.4 million deferred tax valuation allowance release. Adjusted EBITDA remained negative at $(15.8) million for Q4 and $(62.6) million for FY 2025.

• Strong Cash Position Post-SomaLogic Divestiture

  The company reported approximately $550 million in cash and investments following the closing of the SomaLogic transaction on January 30, 2026. This significant capital is intended to fuel an inorganic growth strategy.

• Operationalized Cost Savings and NOL Carryforwards

  Standard BioTools fully operationalized over $40 million in previously announced annualized cost savings and holds approximately $1 billion in Net Operating Loss (NOL) carryforwards for US federal income tax purposes.

• Issues Full Year 2026 Revenue Outlook

  For fiscal year 2026, the company expects revenue in the range of $80 million to $85 million, which is lower than the $85.3 million reported for FY 2025.

auto_awesomeAnalysis

Standard BioTools reported a mixed financial picture, with declining revenue from continuing operations for both Q4 and the full year 2025, and issued a lower revenue outlook for 2026. While net income improved in Q4, this was largely due to a non-cash deferred tax valuation allowance release. However, the company's balance sheet is significantly strengthened by approximately $550 million in cash and investments following the SomaLogic divestiture, a sum that exceeds its current market capitalization. This substantial cash position, coupled with $1 billion in NOL carryforwards, provides significant financial flexibility to pursue inorganic growth and achieve profitability targets, fundamentally altering the company's strategic direction despite ongoing operational challenges.